Executive team

Maurits Huigen

Chief Operating Officer

Maurits Huigen studied information sciences, mathematics and business administration. He has a broad and varied experienced international background in the  Life Sciences Industry by providing strategic advice and consultancy, innovation in market entry & business models and advancing leadership. He worked for Chiesi Pharmaceuticals as managing director, Teva Pharmaceuticals as market group manager and member of the Respiratory Taskforce Europe, as country manager for IVAX Pharmaceuticals and for 3M Pharmaceuticals. He is strategic advisor for the national program for lung research “Lungs Lasting a Lifetime” in the Netherlands.

Frans van Leuven

Chief Legal and Finance Officer

Frans van Leuven has an economic organization consultancy background and is a post-doctoral chartered accountant. He has been acting in fields of stock exchange listed companies and mergers & acquisitions. He specialized in strategic policy, managing crisis situations and corporate law. For 30 years he was partner international business at Deloitte, negotiated on behalf of several companies, which held subsidiaries abroad about their status with local governments. For many years he was an authorized expert at the Tilburg University. In 2008, he moved his field of work to other areas, including the field of pharmaceutical patents

George Hersbach

Chief Executive Officer

George Hersbach holds a Master of Science degree (with distinction) in Chemical Technology, Bioprocess Technology from Delft University of Technology, the Netherlands and a European Engineer degree from FEANI, Paris, France. He is an entrepreneur and corporate manager with many years of experience with private and publicly traded – mostly in biochemical and biopharmaceutical – companies in various countries in Europe and the United States of America.  He is founder and owner of Heartstream Group and active in corporate finance and investments with a focus on healthcare and cleantech. He was a previous CEO for Pharming Group (focused on rare diseases). He worked for EuroCetus/Chiron (now part of Novartis, focused on oncology) as VP operations and for Royal Gist-brocades (now part of DSM) in several international research and development, and manufacturing management positions.


Our Partners

• Lode B.V.
• NHL University of Applied Sciences
• University Medical Centre Utrecht
• TU Delft
• Fluidda



Gilbert Technologies BV
P.O. Box 6
1400 AA Bussum – NL

Gilbert Technologies 2017